LPA and atherosclerosis: The latest ongoing study, currently recruiting, is the ACCLAIM-Lp(a) trial, a phase 3, randomized, double-blind, placebo-controlled study aimed at investigating the effect of lepodisiran on reducing major adverse cardiovascular events (MACEs) in 12,500 participants with established ASCVD or high-risk profiles and elevated Lp(a) levels above 175 nmol/L.